Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Other Non-Current Assets (2021 - 2025)

Krystal Biotech's Other Non-Current Assets history spans 5 years, with the latest figure at $287000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 24.24% year-over-year to $287000.0; the TTM value through Dec 2025 reached $287000.0, up 24.24%, while the annual FY2025 figure was $287000.0, 24.24% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $287000.0 at Krystal Biotech, down from $333000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $402000.0 in Q1 2023 and bottomed at $62000.0 in Q3 2021.
  • The 5-year median for Other Non-Current Assets is $204000.0 (2022), against an average of $211300.0.
  • The largest annual shift saw Other Non-Current Assets skyrocketed 337.84% in 2022 before it plummeted 55.79% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $74000.0 in 2021, then soared by 337.84% to $324000.0 in 2022, then decreased by 18.83% to $263000.0 in 2023, then decreased by 12.17% to $231000.0 in 2024, then increased by 24.24% to $287000.0 in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Other Non-Current Assets are $287000.0 (Q4 2025), $333000.0 (Q3 2025), and $197000.0 (Q2 2025).